Coronavirus-3C-like-proteinase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 Business Days
DelveInsight’s, “Coronavirus-3C-like-proteinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Coronavirus-3C-like-proteinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Coronavirus-3C-like-proteinase inhibitors: Overview
The 3C-like protease (3CLpro), which hydrolyses viral polyproteins to produce functional proteins, is essential for coronavirus replication and is considered an important therapeutic target for diseases caused by coronaviruses, including COVID-19. Coronavirus 3CLpro is a cysteine protease that has two N-terminal domains containing two ?-barrel chymotrypsin-like folds (8–10). The active site of 3CLpro is located in the cleft between the two domains and is characterized by a catalytic Cys-His dyad. Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.
Report Highlights
This segment of the Coronavirus-3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Coronavirus-3C-like-proteinase inhibitors Emerging Drugs
Further product details are provided in the report……..
Coronavirus-3C-like-proteinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Coronavirus-3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Coronavirus-3C-like-proteinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Coronavirus-3C-like-proteinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronavirus-3C-like-proteinase inhibitors drugs.
Coronavirus-3C-like-proteinase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Coronavirus-3C-like-proteinase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Coronavirus-3C-like-proteinase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Coronavirus-3C-like-proteinase inhibitors: Overview
The 3C-like protease (3CLpro), which hydrolyses viral polyproteins to produce functional proteins, is essential for coronavirus replication and is considered an important therapeutic target for diseases caused by coronaviruses, including COVID-19. Coronavirus 3CLpro is a cysteine protease that has two N-terminal domains containing two ?-barrel chymotrypsin-like folds (8–10). The active site of 3CLpro is located in the cleft between the two domains and is characterized by a catalytic Cys-His dyad. Various studies are going on to study this protein in order to identify therapeutics against the SARS-CoV in particular and other pathogenic coronaviruses. A number of patented inhibitors with promising clinical potential have been developed through different methods.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Coronavirus-3C-like-proteinase inhibitors R&D. The therapies under development are focused on novel approaches for Coronavirus-3C-like-proteinase inhibitors.
This segment of the Coronavirus-3C-like-proteinase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Coronavirus-3C-like-proteinase inhibitors Emerging Drugs
- PF 07321332: Pfizer
- S-217622: Shionogi
Further product details are provided in the report……..
Coronavirus-3C-like-proteinase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Coronavirus-3C-like-proteinase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Coronavirus-3C-like-proteinase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Coronavirus-3C-like-proteinase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Coronavirus-3C-like-proteinase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Coronavirus-3C-like-proteinase inhibitors drugs.
Coronavirus-3C-like-proteinase inhibitors Report Insights
- Coronavirus-3C-like-proteinase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Coronavirus-3C-like-proteinase inhibitors drugs?
- How many Coronavirus-3C-like-proteinase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Coronavirus-3C-like-proteinase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Coronavirus-3C-like-proteinase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Coronavirus-3C-like-proteinase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Pfizer
- Shionogi
- SyneuRx International (Taiwan) corp
- AB Science
- Sorrento Therapeutics
- Acrivon Therapeutics
- Exscientia
- Arbutus Biopharma
- Cortexyme
- Aligos Therapeutics
- SOM Biotech
- PF 07321332
- S-217622
- Pentarlandir
- PF 07304814
- MPI 8
- Masitinib
- MPI 1121
- ACR 368
- COR 803
- ALG-097111
- Eravacycline
Introduction
Executive Summary
Coronavirus-3C-like-proteinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Coronavirus-3C-like-proteinase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III and II/III)
Comparative Analysis
PF 07321332: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pentarlandir: SyneuRx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
S 217622: Shionogi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MPI 8: Sorrento Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Coronavirus-3C-like-proteinase inhibitors Key Companies
Coronavirus-3C-like-proteinase inhibitors Key Products
Coronavirus-3C-like-proteinase inhibitors- Unmet Needs
Coronavirus-3C-like-proteinase inhibitors- Market Drivers and Barriers
Coronavirus-3C-like-proteinase inhibitors- Future Perspectives and Conclusion
Coronavirus-3C-like-proteinase inhibitors Analyst Views
Coronavirus-3C-like-proteinase inhibitors Key Companies
Appendix
Executive Summary
Coronavirus-3C-like-proteinase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Coronavirus-3C-like-proteinase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III and II/III)
Comparative Analysis
PF 07321332: Pfizer
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Pentarlandir: SyneuRx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
S 217622: Shionogi
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
MPI 8: Sorrento Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Coronavirus-3C-like-proteinase inhibitors Key Companies
Coronavirus-3C-like-proteinase inhibitors Key Products
Coronavirus-3C-like-proteinase inhibitors- Unmet Needs
Coronavirus-3C-like-proteinase inhibitors- Market Drivers and Barriers
Coronavirus-3C-like-proteinase inhibitors- Future Perspectives and Conclusion
Coronavirus-3C-like-proteinase inhibitors Analyst Views
Coronavirus-3C-like-proteinase inhibitors Key Companies
Appendix